drugset / Trial / NCT02935712
Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)
Phase 1
Completed
44 enrolled
AstraZeneca
14050 · collabBerlin, Germany · collabParexel · collabSpandauer Damm 130 · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This study will be a phase I, first time in human (FiH), randomized, single-blind, placebo-controlled, SAD study in male patients with T2DM, performed at a single study center. The study will consist of 2 parts, (A and B) up to 60 male patients with T2DM aged 18 to 65 years will be included
Timeline
- Start
- 2016-12-16
- Primary completion
- 2017-08-04
- Completion
- 2018-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD8601 | Messenger RNA (mRNA) | 0.004 mg | Other |
Indications
No indication recorded.